The aim of this study was to evaluate an impact of 13-valent conjugate pneumococcal vaccine (PCV-13) and 23-valent polysaccharide pneumococcal vaccine (PPV-23) on quality of life of patients with chronic obstructive pulmonary disease. Methods. We estimated quality of life from baseline to 12 months after the vaccination using the COPD Assessment Test (CAT). Results. The study involved 58 patients with COPD vaccinated with PCV-13 (n = 33) or PPV-23 (n = 25). The CAT score reduced by 10.3 in patients vaccinated with PCV-13 and by 8.8 in patients vaccinated with PPV-23 (p < 0.05). Conclusion. Vaccination of COPD patients with PCV-13 or PPV-23 could significantly improve quality of life. The conjugate vaccine PCV-13 is more preferable. Further studies of microbiological, immunological and other effects of PCV-13 and PPV-23 in COPD patients are needed.

The aim of this study was to evaluate an impact of 13-valent conjugate pneumococcal vaccine (PCV-13) and 23-valent polysaccharide pneumococcal vaccine (PPV-23) on quality of life of patients with chronic obstructive pulmonary disease. Methods. We estimated quality of life from baseline to 12 months after the vaccination using the COPD Assessment Test (CAT). Results. The study involved 58 patients with COPD vaccinated with PCV-13 (n = 33) or PPV-23 (n = 25). The CAT score reduced by 10.3 in patients vaccinated with PCV-13 and by 8.8 in patients vaccinated with PPV-23 (p < 0.05). Conclusion. Vaccination of COPD patients with PCV-13 or PPV-23 could significantly improve quality of life. The conjugate vaccine PCV-13 is more preferable. Further studies of microbiological, immunological and other effects of PCV-13 and PPV-23 in COPD patients are needed.

The aim of this study was to compare functional status of patients with chronic obstructive pulmonary disease (COPD) vaccinated by combined vaccine vs single vaccine against influenza and a control group. Methods . The study involved 170 patients with COPD stage I to IV. Of them, 50 patients were vaccinated with a combined vaccine against pneumococcus, Haemophilus influenzae type b and influenza; 80 patients with equal COPD severity were not vaccinated and were treated with basic therapy; 20 COPD patients were vaccinated with a single vaccine against influenza, and 20 COPD patients were not vaccinated. Lung function and physical tolerability at 6 - min walk test were assessed at baseline and in 12 months. Results . A significantly higher FEV 1 (57.4 ± 2.0 % vs 50.4 ± 2.8 %) was found in COPD patients vaccinated with a combined vaccine compared to unvaccinated COPD patients; the difference between baseline FEV 1 and FEV 1 in 12 months after vaccination was 3.5 % vs 2.11 %, respectively. The improvement in 6 - min distance was + 34 m (+ 7.4 %) in combined vaccine group compared to + 13 m (+ 3.7 %) in influenza vaccine group. Conclusion . COPD patients vaccinated with a combined vaccine against bacterial pathogens plus influenza better improved their lung function and physical tolerability compared to COPD patients vaccinated with a single vaccine against influenza.

Summary. The follow-up involved 201 adults with chronic obstructive pulmonary disease – COPD (100 were city dwellers and 101 were rural inhabitants). Of them, 100 patients were vaccinated against pneumococcal infection using the pneumococcal polysaccharide vaccine PPSV23, 101 patients were not vaccinated and formed the control group. We analyzed a rate and severity of COPD exacerbations 1 year before and after the vaccination. Vaccinated urban and rural residents with COPD demonstrated a 2.4-fold and a 2.5-fold decrease in the exacerbation rate, respectively. Among all vaccinated patients, 58 % of rural inhabitants and 25 % of city dwellers with COPD did not have COPD exacerbations during the year after the vaccination. The observed clinical effect demonstrated that PPSV23 can be used as one of tools to maintain the public health and to increase life expectancy.

Summary. The follow-up involved 201 adults with chronic obstructive pulmonary disease – COPD (100 were city dwellers and 101 were rural inhabitants). Of them, 100 patients were vaccinated against pneumococcal infection using the pneumococcal polysaccharide vaccine PPSV23, 101 patients were not vaccinated and formed the control group. We analyzed a rate and severity of COPD exacerbations 1 year before and after the vaccination. Vaccinated urban and rural residents with COPD demonstrated a 2.4-fold and a 2.5-fold decrease in the exacerbation rate, respectively. Among all vaccinated patients, 58 % of rural inhabitants and 25 % of city dwellers with COPD did not have COPD exacerbations during the year after the vaccination. The observed clinical effect demonstrated that PPSV23 can be used as one of tools to maintain the public health and to increase life expectancy.

AIM:Evaluation of postvaccination immunity against influenza in patients with bronchopulmonary pathology.MATERIALS AND METHODS:22 patients with broncho-pulmonary pathology vaccinated against influenza with Grippol plus preparation participated in the study. Rates of influenza and acute respiratory illnesses (ARI), rates and duration of exacerbations of the underlying disease were tracked based on medical documents. Hemagglutination inhibition reaction in paired sera before and 6 and 12 months after the vaccination was used to evaluate vaccine immunogenicity.RESULTS:None of the patients had influenza diagnosis for one year. A reduction of ARI rate of 37% was detected. Rate of exacerbation of the underlying disease decreased by 1.9 times, duration of exacerbations--by 2 times. Data on immunogenicity against A/H1N1/ Brisbane/59/07, A/H3N2/Uruguay/716/2007, B/ Florida/4/2006 are presented. Immunogenicity against B/Brisbane/60/2008 strain not contained in the vaccine was insufficient to induce adequate protection. Statistically significant differences were not detected during comparison of immunogenicity in patients with broncho-pulmonary pathology and healthy people.CONCLUSION:Grippol plus vaccine in patients with respiratory tract diseases is immunogenic and renders clinical effect by reducing influenza morbidity and rate of exacerbation of the underlying disease.